The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

L'Oreal (EPA:OR) stock pared back some of its early losses on Monday after announcing the sale of 29.6 million shares of its ...

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of 10.3% at CER 1and business EPS 2of €1.

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.71. Thomas Larsen: Welcome to the Q4 and Full Year 2024 Conference Call ...

Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Welcome to the Q4 and full year 2024 conference call ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.